New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2014
08:08 EDTSNY, REGNSanofi and Regeneron report positive Phase 2 results of alirocumab
Sanofi (SNY) and Regeneron (REGN) announced that nine new Phase 3 Odyssey trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol at 24 weeks compared to placebo or active comparator. In the nine trials, the mean percent reduction in LDL-C from baseline at 24 weeks in alirocumab-treated patients was consistent with results seen in previous alirocumab trials. A lower rate of adjudicated major cardiovascular events was observed in the alirocumab arm compared to placebo in a post-hoc analysis. The potential of alirocumab to demonstrate cardiovascular benefit is being prospectively assessed in an ongoing 18,000-patient Odyssey Outcomes trial. Alirocumab was generally well tolerated in the 9 trials.
News For SNY;REGN From The Last 14 Days
Check below for free stories on SNY;REGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
06:18 EDTSNYSanofi, MyoKardia announce collaboration
Subscribe for More Information
September 16, 2014
07:33 EDTSNYMylan initiates Phase III clinical trials for Advair Diskus and Lantus
Mylan (MYL) announced it is initiating Phase III clinical trials for its generic version of GlaxoSmithKline's (GKS) Advair Diskus and its insulin analog to Sanofi's (SNY) Lantus. In October Mylan will commence a Phase III clinical trial to evaluate the equivalence of its product to Advair Diskus when administered by inhalation in adult asthma patients.
07:31 EDTREGNRegeneron's EYLEA Injection granted designation for treatment of retinopathy
Subscribe for More Information
September 12, 2014
10:04 EDTSNYSanofi unit granted orphan status for treatment of Gaucher disease
Subscribe for More Information
September 11, 2014
05:27 EDTSNYGenzyme announces positive interim results from Lemtrada extension study
Subscribe for More Information
September 10, 2014
07:09 EDTSNYAmericas Committee for Treatment & Research in MS to hold a meeting
Subscribe for More Information
September 8, 2014
14:16 EDTSNYSanofi announces FDA approval of Menactra vaccine
Subscribe for More Information
07:15 EDTREGNIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use